Loading company…
Maxinovel Pharmaceuticals researches and develops targeted and immune therapies for cancer.
Maxinovel Pharmaceuticals develops small molecule targeted drugs, tumor immune drugs, and other medicines for conditions including acute myeloid leukemia and solid tumors. Founded in 2016, it is based in Guangzhou, China, with R&D and operations centers in Shanghai, Guangzhou, and Shenzhen. Its product Max-40279 received U.S. FDA orphan drug status in April 2018.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in